Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apatinib + pegylated liposomal doxorubicin
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of apatinib (also known as rivoceranib) and pegylated liposomal doxorubicin (PLD). Apatinib is an oral, small-molecule tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptor 2 (VEGFR-2), thereby inhibiting tumor-induced angiogenesis. Pegylated liposomal doxorubicin is a liposomal formulation of the anthracycline topoisomerase II inhibitor doxorubicin, designed to enhance drug delivery to tumor tissues while minimizing cardiotoxicity and other systemic side effects. This combination was evaluated by the Chinese Academy of Medical Sciences in the Phase 2 APPROVE trial for the treatment of platinum-resistant recurrent ovarian cancer, where it demonstrated a significant improvement in progression-free survival compared to PLD monotherapy.
- Brand names
- Aitan
- Other names
- apatinib + PLDrivoceranib + pegylated liposomal doxorubicinapatinib + liposomal doxorubicin
02
Targets
TOP2A (DNA topoisomerase II)VEGFR2 (Vascular endothelial growth factor receptor 2)DNA
Beyond the preview
Go deeper on apatinib + pegylated liposomal doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apatinib + pegylated liposomal doxorubicin.